CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.

The interaction of PD-L1 with PD-1 is a major immune checkpoint that limits effector T cell function against cancer cells; monoclonal antibodies that block this pathway have been approved in multiple tumor indications. As a next generation therapy, small molecule inhibitors of PD-L1 have inherent dr...

Full description

Bibliographic Details
Main Authors: Kathleen M C Sullivan, Marta Vilalta, Linda S Ertl, Yu Wang, Carolyn Dunlap, Karen Ebsworth, Bin N Zhao, Shijie Li, Yibin Zeng, Zhenhua Miao, Pingchen Fan, Venkat Mali, Christopher Lange, Darren McMurtrie, Ju Yang, Rebecca Lui, Ryan Scamp, Vicky Chhina, Alice Kumamoto, Simon Yau, Ton Dang, Ashton Easterday, Shirley Liu, Shichang Miao, Israel Charo, Thomas J Schall, Penglie Zhang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0286724

Internet

https://doi.org/10.1371/journal.pone.0286724

Similar Items